Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
TWST submitted a Form 144 notice reporting proposed sales of Common Stock by an affiliate. The excerpt lists four recent sale entries: 425 shares on 03/06/2026, 354 shares on 03/20/2026, 1,962 shares on 05/04/2026, and 1,642 shares on 05/21/2026, each with the dollar amounts shown. The filing also lists routine issuer grant and ESPP vesting events dated 2022–2024.
TWST filed a Form 144 reporting proposed and recent dispositions of Common Stock by an affiliated party. The filing lists scheduled restricted stock vesting events on 07/08/2025, 08/20/2025, and 05/20/2026 totaling 4,000 shares in one line item and additional individual grants of 1,716; 592; and 1,692 shares. The filing also reports four recent sales by Adam Laponis: 2,597 shares on 04/09/2026, 3,000 shares on 04/14/2026, 4,000 shares on 04/17/2026, and 2,019 shares on 05/21/2026, with dollar amounts shown for each transaction.
Twist Bioscience Corporation reported insider resale activity via Form 144 indicating sales of common stock by Emily M. Leproust on multiple dates in 2026. The filing lists individual block dispositions with cash proceeds for each sale and notes an option-related sale dated 05/28/2026 tied to an option granted 09/29/2017.
Twist Bioscience Corp director Melissa A. Starovasnik sold 500 shares of Common Stock in an open-market transaction. The sale occurred on May 26, 2026 at a price of $61.04 per share. After this transaction, she continues to hold 24,722 shares directly. The company notes that this trade was carried out under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than a discretionary market-timing decision.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an exercise-and-sell transaction under a pre-arranged Rule 10b5-1 trading plan. She exercised options to acquire a total of 49,299 shares of common stock at an exercise price of $8.82 per share and sold the same number of shares in open-market transactions.
The sales covered 24,282 shares at a weighted average price of $65.0789 per share, 23,752 shares at $65.2392 per share, and 1,265 shares at $66.2813 per share. After these transactions, she continues to hold 846,872 shares of Twist Bioscience common stock directly, along with remaining employee stock options, including awards exercisable into 64,950 shares at an exercise price of $67.85 per share.
Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported a small mandated stock sale to cover taxes. On the transaction date, he sold 800 shares of common stock in an open-market transaction at an average price of $62.484 per share.
According to the footnote, this sale was required to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. After this sale, Werner directly holds 48,186 shares of Twist Bioscience common stock.
TWST submitted a Form 144 notice relating to 2,500 shares of Common Stock tied to a restricted stock vesting event dated 02/07/2024. The filing lists prior sales of 1,000 shares on 04/01/2026 for $51,000, 500 shares on 04/27/2026 for $30,915, and 500 shares on 05/26/2026 for $30,520.
TWST: Notice of proposed sales under Rule 144 by Emily M. Leproust. The filing lists multiple proposed dispositions of Common Stock by Emily M. Leproust, including a sale of 24,282 shares for $1,580,246.60 on 05/26/2026 and earlier listed transactions in March–May 2026. The filing also notes an option granted 09/29/2017.
Form 144 filing reports a planned sale of 24,282 shares of Common Stock on 05/26/2026. The filing lists prior open-market dispositions by Emily M. Leproust during the past three months, including 2,423 shares on 03/06/2026, 8,061 shares on 04/22/2026, and 6,888 shares on 05/21/2026.
Twist Bioscience Corp SVP of Human Resources Paula Green reported an open-market sale of 1,399 shares of common stock at $53.257 per share. According to the footnote, this transaction was a mandated “sell to cover” to satisfy tax withholding obligations tied to vesting Restricted Stock Units, rather than a discretionary trade. After the sale, she directly holds 121,589 shares of Twist Bioscience common stock.